Kristen Albright is the founder of Prokarium. Prokarium has raised $30M in total funding. Latest round: Series B. Based in London, United Kingdom.
Kristen Albright, PharmD, is the CEO of Prokarium, a London-based biotechnology company focused on creating targeted oral vaccines and immunotherapies for difficult-to-treat cancers. She played a pivotal role in securing $30 million in funding and spearheading synthetic biology R&D collaborations for Prokarium in 2023. Prior to her CEO appointment, she served as Vice President of BD and Translational Research at the company.
Full founder directory · Investor directory · Company funding database · Fundraising library